Regarding the standardized consumption in osteoporosis medication, HHDs explained a substantial part (39%) of the variance between PHZs (Table 3), ranging from 33% (biphosphonates or raloxifene) to 58% (parathyroid hormones) depending on the therapeutic group. The gene discussed is PTH; the disease is osteoporosis.